Gardasil HPV Vaccine
OpenFASTCausation
Plaintiffs allege Gardasil HPV vaccine triggers autoimmune and neurological injuries through molecular mimicry — the aluminum adjuvant (AAHS) and HPV L1 protein fragments provoke an aberrant immune response attacking the body own nervous system. Reported injuries include postural orthostatic tachycardia syndrome (POTS), complex regional pain syndrome (CRPS), premature ovarian failure (POF), small fiber neuropathy, and chronic fatigue syndrome. Plaintiffs allege Merck inadequately tested Gardasil, used an aluminum-containing placebo in clinical trials to mask adverse event rates, and failed to warn about autoimmune risks. Cases are filed in civil court (not VICP) under the theory that Merck committed fraud on the FDA.
Defendants
| Entity | Role | Note |
|---|---|---|
| Merck & Co., Inc. | Manufacturer | Sole manufacturer of Gardasil and Gardasil 9 HPV vaccines |
| Merck Sharp & Dohme Corp. | Subsidiary | Merck subsidiary — named in product liability claims |
Litigation Timeline
Intelligence Signals
No signals yet. Signals populate automatically when scrapers run.
Key Facts
- Status
- active
Geographic Exposure
Eligibility Criteria
- ✓Received Gardasil or Gardasil 9 HPV vaccine
- ✓Developed autoimmune disorder (POTS, CRPS, POF, small fiber neuropathy) after vaccination
- ✓Onset of symptoms within weeks to months of vaccination
- ✓No pre-existing autoimmune condition before vaccination